Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-12-14 00:00:00 ET · period of report 2022-12-12 · accession 0000899243-22-038478 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-12-14 | 2022-12-12 | LGND | HIGGINS JOHN L | Dir | M - OptEx | $12.78 | +20.0K | 436.9K | +5% | +$255.6K |
| D | 2022-12-14 | 2022-12-12 | LGND | HIGGINS JOHN L | Dir | D - Sale to Iss | $64.80 | -3,944 | 433.0K | -0.9% | -$255.6K |
| D | 2022-12-14 | 2022-12-12 | LGND | HIGGINS JOHN L | Dir | M - OptEx | $0.00 | -20.0K | 20.3K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-12-12 | M | A | 20,000 | $12.78 | 436,928 | D | — | — | |
| 2 | Common | Common Stock | 2022-12-12 | D | D | 3,944 | $64.80 | 432,984 | D | — | — | |
| 3 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-12-12 | M | D | 20,000 | $0.00 | 20,335 | D | $12.78 · — to 2023-02-15 | 20,000 Common Stock | (F1) Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The original date of grant was 02/15/13. |